Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Caribou Biosciences, Inc.CRBU · Entity 6445 | Chief Legal Officer | February 20, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Caribou Biosciences, Inc.
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 481,564 |
Ending reported balance
After 2026-02-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-20 · Grant · Acquired 45,000 · Balance 488,502 F1: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Row 2 · 2026-02-24 · Sale · Disposed 6,938 · Balance 481,564 F2: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2036-02-19 | Direct | 202,500 |
Reported balance
After 2026-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-20 · Grant · Acquired 202,500 · Balance 202,500 F3: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.
F2: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.
F3: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2026 Filed Feb 24, 2026 20:54 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | SaleCommon Stock | 6,938 | $1.96 | $13,598.48 |
DisclosureSEC source: 0001231321-26-000002 · wk-form4_1771984473.xml · nonDerivative · entry 2 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 481,564 F2 · kind: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. F2 · shares: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 20:54 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 202,500 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001231321-26-000002 · wk-form4_1771984473.xml · derivative · entry 3 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,500 Underlying: Common Stock · 202,500 shares Expires 2036-02-19 F3 · derivative.exercise_date: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 20:54 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001231321-26-000002 · wk-form4_1771984473.xml · nonDerivative · entry 1 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488,502 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| February 21, 2025 Filed Feb 21, 2025 20:19 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | SaleCommon Stock | 3,564 | $1.35 | $4,811.40 |
DisclosureSEC source: 0001231321-25-000003 · wk-form4_1740187189.xml · nonDerivative · entry 2 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,502 F2 · kind: Reflects the number of shares of common stock that were sold in a "sell to cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. F2 · shares: Reflects the number of shares of common stock that were sold in a "sell to cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. F3 · price: This transaction was executed in multiple trades on 2/21/2025 at prices ranging from $1.32 to $1.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the specified range. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 20:19 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 170,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001231321-25-000003 · wk-form4_1740187189.xml · derivative · entry 3 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2035-02-19 F4 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2026, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 20:19 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001231321-25-000003 · wk-form4_1740187189.xml · nonDerivative · entry 1 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 447,066 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2026, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 17:24 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 153,000 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001628280-24-006429 · wk-form4_1708640636.xml · derivative · entry 2 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,000 Underlying: Common Stock · 153,000 shares Expires 2034-02-19 F2 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2025, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 17:24 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-006429 · wk-form4_1708640636.xml · nonDerivative · entry 1 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,566 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2025, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 17:10 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 131,000 | $0.00 Strike: $6.12 | $0.00 |
DisclosureSEC source: 0001619856-23-000021 · wf-form4_167719018333486.xml · derivative · entry 1 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,000 Underlying: Common Stock · 131,000 shares Expires 2033-02-20 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on February 21, 2027, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 16:14 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 27,518 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-22-050315 · doc4.xml · derivative · entry 4 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,318 Underlying: Common Stock · 27,518 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on October 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 16:14 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 77 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-22-050315 · doc4.xml · derivative · entry 3 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77 shares Expires 2028-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option vested in equal monthly installments until the option became fully vested on June 12, 2022. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 16:14 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 27,518 | $2.69 | $74,023.42 |
DisclosureSEC source: 0001209191-22-050315 · doc4.xml · nonDerivative · entry 2 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 16:14 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 77 | $2.69 | $207.13 |
DisclosureSEC source: 0001209191-22-050315 · doc4.xml · nonDerivative · entry 1 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 17:31 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 147,000 | $0.00 Strike: $15.16 | $0.00 |
DisclosureSEC source: 0001209191-21-070814 · doc4.xml · derivative · entry 1 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,000 Underlying: Common Stock · 147,000 shares Expires 2031-12-19 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on December 20, 2025, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 18:06 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | OtherOption to purchase Common Stock · Derivative | 6,115 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-21-068582 · doc4.xml · derivative · entry 4 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,836 Underlying: Common Stock · 6,115 shares Expires 2029-09-30 F2 · derivative.exercise_price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. F4 · derivative.exercise_date: The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on October 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 18:06 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | OtherOption to purchase Common Stock · Derivative | 12 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-21-068582 · doc4.xml · derivative · entry 3 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77 Underlying: Common Stock · 12 shares Expires 2028-06-11 F2 · derivative.exercise_price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. F3 · derivative.exercise_date: The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on June 12, 2022, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 18:06 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | PurchaseCommon Stock | 6,115 | $2.69 | $16,449.35 |
DisclosureSEC source: 0001209191-21-068582 · doc4.xml · nonDerivative · entry 2 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,971 F1 · kind: These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below. F2 · price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 18:06 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | PurchaseCommon Stock | 12 | $2.69 | $32.28 |
DisclosureSEC source: 0001209191-21-068582 · doc4.xml · nonDerivative · entry 1 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,856 F1 · kind: These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below. F2 · price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. Read SEC document |
| October 20, 2021 Filed Oct 21, 2021 18:12 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | OtherOption to purchase Common Stock · Derivative | 43 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-21-061294 · doc4.xml · derivative · entry 4 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89 Underlying: Common Stock · 43 shares Expires 2028-06-11 F2 · derivative.exercise_price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. F5 · derivative.exercise_date: The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on June 12, 2022, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| October 20, 2021 Filed Oct 21, 2021 18:12 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | OtherOption to purchase Common Stock · Derivative | 9,176 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-21-061294 · doc4.xml · derivative · entry 3 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,951 Underlying: Common Stock · 9,176 shares Expires 2029-09-30 F2 · derivative.exercise_price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. F4 · derivative.exercise_date: The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on October 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| October 20, 2021 Filed Oct 21, 2021 18:12 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | PurchaseCommon Stock | 43 | $2.69 | $115.67 |
DisclosureSEC source: 0001209191-21-061294 · doc4.xml · nonDerivative · entry 2 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,844 F1 · kind: These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below. F2 · price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. Read SEC document |
| October 20, 2021 Filed Oct 21, 2021 18:12 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | PurchaseCommon Stock | 9,176 | $2.69 | $24,683.44 |
DisclosureSEC source: 0001209191-21-061294 · doc4.xml · nonDerivative · entry 1 MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,801 F1 · kind: These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below. F2 · price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. F3 · balance_after: The amount of securities beneficially owned was incorrectly reported as 333,626 shares on the reporting person's Form 3 filed on July 22, 2021. The correct number is 333,625. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.